Interim Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Antibody to Programmed Death-1, in Patients with Locally Advanced Cutaneous Squamous Cell Carcinoma

Main Article Content

Michael R Migden
Carola Berkin
Anne Lynn Chang
Et al.

Keywords

Abstract

Abstract not available.

 

Disclosures: Study sponsored by Regeneron Pharmaceuticals and Sanofi.

 

Copyright 2018 SKIN